OPT 0.60% 83.5¢ opthea limited

Ann: Opthea Granted Japanese Patent Covering OPT-302, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 824 Posts.
    lightbulb Created with Sketch. 44
    Opthea Ltd. (OPT) reported the grant of Japanese patent covering both OPT-302 and compositions containing OPT-302 for use in treating disorders associated with aberrant angiogenesis and/or lymphangiogenesis, including eye diseases such are wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Patents covering Opthea's OPT-302 and extending out to 2034 have now been granted in Japan, the U.S.A., Australia, South Africa and Singapore and applications are pending in a further 14 countries

    http://crweworld.com/article/news-provided-by-globenewswire/957450/opthea-granted-japanese-patent-covering-opt-302

     
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
(20min delay)
Last
83.5¢
Change
-0.005(0.60%)
Mkt cap ! $1.027B
Open High Low Value Volume
85.5¢ 85.5¢ 82.0¢ $11.20M 13.42M

Buyers (Bids)

No. Vol. Price($)
1 13018 83.0¢
 

Sellers (Offers)

Price($) Vol. No.
84.0¢ 3897 1
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.